Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

AUTO3 CAR T cells targeting CD19 and CD22 reported effective in r/r DLBCL

Key clinical point: AUTO3 at > 50 x 106 CAR T cells with pembrolizumab induces CRs without severe CRS or neurotoxicities of any grade.

Major finding: Among 11 patients treated at dose > 50 x 106 cells, the ORR and CRR were 64% and 55%, respectively.

Study details: A total of 19 DLBCL patients were treated with AUTO3; 18 of whom were evaluable for efficacy.

Disclosures: The abstract did not provide conflict information.


Osborne W et al. European Hematology Association virtual annual meeting. 2020; Abstract S240.